What is Kinomica?
Founded in 2016, Kinomica operates at the intersection of data science and molecular biology. The company specializes in the complex field of cell signaling, providing high-resolution insights that are essential for drug discovery and precision medicine. By mapping the kinome—the complete set of protein kinases in a cell—Kinomica enables researchers and clinicians to understand disease mechanisms with unprecedented clarity. This diagnostic capability is increasingly vital for the development of targeted therapies, positioning the company as a key partner for pharmaceutical enterprises seeking to optimize their pipeline efficiency and patient stratification strategies.
How much funding has Kinomica raised?
Kinomica has raised a total of $5.2M across 1 funding round:
Unspecified
$5.2M
Unspecified (2020): $5.2M with participation from Puffin Point, BioCity Group Limited, Alderley Park, Longwall Ventures, and BGF Ventures
Key Investors in Kinomica
Longwall Ventures
Longwall Ventures invests in early stage deeptech businesses that leverage the UK's expertise in science R&D, focusing on addressing global challenges through innovative solutions.
BGF Ventures
BGF is the most active equity investor in the UK and Ireland, providing long-term, minority investment and value creation support to growing companies looking to scale-up.
BioCity Group Limited
BioCity Group Limited is a prominent life sciences incubator and investor, providing essential infrastructure and strategic support to early-stage biotech and healthcare ventures.
What's next for Kinomica?
With the infusion of this major strategic investment, Kinomica is poised to scale its commercial operations and expand its footprint within the global diagnostics market. The strategic roadmap likely involves the further validation of its proteomic-data platforms in clinical settings and the strengthening of its intellectual property portfolio. As the company transitions into a more mature lifecycle stage, the focus will shift toward establishing long-term partnerships with global biopharmaceutical firms. This expansion will be critical in translating its deeptech research into scalable, high-impact diagnostic solutions that address unmet needs in oncology and chronic disease management.
See full Kinomica company page
